Assess aspirin benefit vs. harm for primary cardiovascular prevention. USPSTF 2022: initiate low-dose aspirin for adults 40-59 with 10% or more 10-year CVD risk (Grade C, shared decision). Adults 60 or older: do not initiate (Grade D) due to increased bleeding outweighing benefit.
Enter the values for the scenario you are assessing. Assess aspirin benefit vs. harm for primary cardiovascular prevention. USPSTF 2022: initiate low-dose aspirin for adults 40-59 with 10% or more 10-year CVD risk (Grade C, shared decision). Adults 60 or older: do not initiate (Grade D) due to increased bleeding outweighing benefit. Use the aspirin primary prevention result to inform your calculation.